Novel Oral TYK2 Inhibitors Achieve Simultaneous Phase 3 Success for Atopic Dermatitis and Psoriasis

For millions of people living with severe eczema and psoriasis, the treatment landscape has long forced a frustrating compromise. Patients have historically had to choose between the limited efficacy of daily topical creams, the broad immune suppression of older systemic pills, or the high cost and logistical hurdles of biologic injections.

That paradigm is now rapidly shifting. On August 24, 2026, InnoCare Pharma announced that two of its novel oral TYK2 inhibitors—soficitinib and fadeucravacitinib—simultaneously met their primary endpoints in Phase 3 clinical trials for atopic dermatitis and psoriasis, respectively.[5]

This dual milestone caps a blockbuster year for the TYK2 inhibitor class. Throughout 2026, late-stage trial data for rival compounds like zasocitinib and envudeucitinib have consistently demonstrated that these once-daily pills can achieve skin clearance rates previously thought possible only with injectable biologics.[1][4]

To understand why these drugs are succeeding where older pills failed, it helps to look at the immune system's signaling architecture. Psoriasis and atopic dermatitis are driven by inflammatory cytokines, particularly interleukin-23 (IL-23) and Type 1 interferons. These signals rely on an enzyme called Tyrosine Kinase 2 (TYK2) to transmit their instructions into the cell nucleus.[2][3]

TYK2 belongs to the Janus kinase (JAK) family. Older JAK inhibitors block multiple enzymes in this family (JAK1, JAK2, JAK3), which effectively halts the skin inflammation but also suppresses broader immune functions, leading to black-box warnings for cardiovascular risks and infections. The new generation of TYK2 inhibitors bypasses this problem by binding to a unique structural pocket called the JH2 pseudokinase domain. This makes them hyper-selective; zasocitinib, for instance, is reportedly one million times more selective for TYK2 than for other JAK enzymes.[2][3]

The clinical data supporting this targeted approach is robust. In the Phase 3 LATITUDE trials, zasocitinib enabled over 50% of psoriasis patients to achieve a PASI 90 response (90% skin clearance) by week 16. Roughly a third achieved PASI 100, meaning completely clear skin.[3][4]

Similarly, the TYK2 inhibitor envudeucitinib demonstrated PASI 75 clearance in over 70% of patients at 16 weeks in its ONWARD Phase 3 trials. By week 24, complete clearance (PASI 100) rates approached 40%. These figures significantly outperform older oral options like apremilast and begin to rival the efficacy of injectable biologics.[1][3]

In atopic dermatitis, where the itch-scratch cycle severely degrades quality of life, the evidence is equally compelling. Soficitinib's Phase 3 success builds on earlier data showing that the drug reduced Eczema Area and Severity Index (EASI) scores by up to 78% within just four weeks, rapidly alleviating intense pruritus (itching).[5]

The efficacy of these drugs extends to notoriously difficult-to-treat areas. Takeda reported that roughly 75% of patients with scalp psoriasis and 70% with palmoplantar (hands and feet) disease achieved clear or almost clear skin at week 16 on zasocitinib.[4]

Crucially, the safety data across these Phase 3 programs has remained clean. Researchers have not observed the laboratory abnormalities, major adverse cardiovascular events (MACE), or tuberculosis reactivations historically associated with broader JAK inhibitors.[1][2]

The most common side effects reported were mild upper respiratory tract infections, nasopharyngitis, and acne. While treatment-emergent adverse events were slightly higher than placebo, serious adverse events remained low, typically around 3%.[3][4]

However, the evidence does have limitations. While the 16-to-24-week clearance rates are unprecedented for oral drugs, long-term safety and durability data beyond two years remain sparse. The dermatology community is still waiting to see if any subtle class-wide side effects emerge when these highly selective inhibitors are used in broader, real-world populations over decades.[2]

Furthermore, direct head-to-head trials against the absolute most potent IL-17 and IL-23 injectable biologics are still needed. While TYK2 inhibitors are closing the gap, top-tier biologics still reliably push PASI 100 rates above 50% in many trials.[1][2]

Pediatric safety and efficacy also remain an open question. While trials for younger patients are planned or underway, the current Phase 3 data applies almost exclusively to adults.[1]

Despite these unknowns, the simultaneous Phase 3 successes across multiple drugs and conditions signal a definitive turning point. For patients averse to needles or facing logistical barriers to biologic access, the arrival of highly effective, highly selective oral TYK2 inhibitors offers a profound upgrade in the standard of care.[3][5]